<DOC>
	<DOCNO>NCT01538511</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial compare biphasic insulin aspart 70 ( NN2000-Mix70 ) subject type 2 diabetes biphasic insulin aspart 30 ( NN-X14Mix30 ) healthy volunteer .</brief_summary>
	<brief_title>Insulin Profile Biphasic Insulin Aspart 70 That Biphasic Insulin Aspart 30 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>SUBJECTS WITH TYPE 2 DIABETES Subjects type 2 diabetes mellitus Current treatment use intermediateacting , longacting premixed/biphasic insulin preparation ( include insulin analogue ) twice daily ( breakfast dinner ) treatment regimen least 12 week ( temporary use [ maximum one week total ] rapidacting human insulin allow ) Age 2069 year , inclusive HbA1c ( glycosylated haemoglobin A1c ) 9.0 % Body Mass Index ( BMI ) 18.525.0 kg/m^2 Total daily insulin dose ( per day ) 0.2 U IU/kg body weight 1.0 U IU/kg body weight HEALTHY VOLUNTEERS Japanese subject consider generally healthy base medical history physical examination Age 2029 year , inclusive Body Mass Index ( BMI ) 18.525.0 kg/m^2 Subjects normal glucose tolerance ( NGT ) ; define fast plasma glucose 110 mg/dL 2hour post OGTT ( oral glucose tolerance test ) plasma glucose 140 mg/dL SUBJECTS WITH TYPE 2 DIABETES Proliferative retinopathy maculopathy require acute treatment Impaired hepatic function Impaired renal function Serious cardiac disease Uncontrolled hypertension Known hypoglycaemia unawareness recurrent major hypoglycaemia Current treatment expect screening start treatment systemic corticosteroid HEALTHY VOLUNTEERS Any clinical laboratory value deviate reference range laboratory ( except case within physiological change ) screen History presence diabetes , cancer clinically significant cardiac , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , dermatological , venereal , haematological , neurological , psychiatric disease disorder Subjects firstdegree relative diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>